Litcius/Paper detail

Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression

Xuejun Wen, Peng‐Fei Xu, Xinying Zeng, Jia Liu, Chao Du, Xueyuan Zeng, Xingxing Cheng, Xueqi Wang, Yuanyuan Liang, Tianzhi Zhao, Hongzhang Yang, Huifeng Li, Lingxin Meng, Jianyang Fang, Hongwu Liu, Zijian Zhou, Jingjing Zhang, Xianzhong Zhang, Zhide Guo, Xiaoyuan Chen

2023European Journal of Nuclear Medicine and Molecular Imaging43 citationsDOI

Topics & Concepts

RadioligandBiodistributionPharmacokineticsProstate cancerRadionuclide therapyEvans BlueCancer researchMedicineIC50Spect imagingGlutamate carboxypeptidase IINuclear medicineChemistryCancerPharmacologyIn vitroInternal medicineReceptorBiochemistryRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchPeptidase Inhibition and Analysis
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression | Litcius